Dr. Arvind Madan, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 290
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME77533
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
- Orlando Health Orlando, FL
Medical groups
- Central Florida Kidney Specialists Inc (40 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 290
- Services billed
- 1,561
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 665 | 201 |
| Established patient office or other outpatient visit, 30-39 minutes | 276 | 87 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 200 | 11 |
| Insertion of needle into vein for collection of blood sample | 175 | 66 |
| Hemodialysis procedure with physician evaluation | 156 | 56 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 127 | 114 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 87 | 18 |
| Blood test, comprehensive group of blood chemicals | 73 | 43 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 70 | 42 |
| Phosphate level | 57 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Torsemide Other prescribers in Orlando, FL | 37 |
| Furosemide Other prescribers in Orlando, FL | 37 |
| Procrit (epoetin alfa) | 35 |
| Xphozah (tenapanor hcl) | 32 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Orlando, FL | 28 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Orlando, FL | 23 |
| Amlodipine Besylate Other prescribers in Orlando, FL | 22 |
| Tamsulosin Hcl Other prescribers in Orlando, FL | 20 |
| Losartan Potassium Other prescribers in Orlando, FL | 20 |
| Nifedipine Er (nifedipine) Other prescribers in Orlando, FL | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 293 payments worth $204,529 in total to this clinician.
| Novo Nordisk Inc | $46,796 |
|---|---|
| Novartis Pharmaceuticals Corporation | $39,004 |
| Mallinckrodt Hospital Products Inc. | $34,357 |
| Akebia Therapeutics Inc | $30,011 |
| Kyowa Kirin, Inc. | $18,673 |
| Amgen Inc. | $12,374 |
| Calliditas Therapeutics US Inc. | $7,754 |
| AstraZeneca Pharmaceuticals LP | $5,520 |
| Compensation for services other than consulting (speaking, faculty) | $125,487 |
|---|---|
| Consulting Fee | $44,120 |
| Travel and Lodging | $24,227 |
| Food and Beverage | $8,716 |
| Honoraria | $1,800 |
| Education | $179 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Feb 28, 2025 | Consulting Fee | $11,350 |
| Calliditas Therapeutics US Inc. Dec 16, 2025 | Consulting Fee TARPEYO · NEPHROLOGY | $7,420 |
| Novartis Pharmaceuticals Corporation Jul 18, 2025 | Consulting Fee Fabhalta · Immunology | $7,200 |
| Mallinckrodt Hospital Products Inc. Nov 12, 2025 | Consulting Fee ACTHAR · IMMUNOLOGY | $6,060 |
| Mallinckrodt Hospital Products Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $6,060 |
| Mallinckrodt Hospital Products Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $6,060 |
| Novo Nordisk Inc Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $5,586 |
| Kyowa Kirin, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,355 |
| Novartis Pharmaceuticals Corporation Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) Vanrafia · Nephrology | $5,200 |
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,987 |
All 124 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Mallinckrodt Hospital Products Inc. Dec 23, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to VERNON HILLS, IL | $192 |
| Mallinckrodt Hospital Products Inc. Dec 23, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to VERNON HILLS, IL | $25.20 |
| Mallinckrodt Hospital Products Inc. Dec 23, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to VERNON HILLS, IL | $24.00 |
| Vertex Pharmaceuticals Incorporated Dec 17, 2025 | Consulting Fee | $2,503 |
| Calliditas Therapeutics US Inc. Dec 16, 2025 | Consulting Fee TARPEYO · NEPHROLOGY | $7,420 |
| Novartis Pharmaceuticals Corporation Dec 7, 2025 | Travel and Lodging travel to Riverside, CA | $984 |
| Novartis Pharmaceuticals Corporation Dec 7, 2025 | Travel and Lodging travel to Riverside, CA · in-kind | $303 |
| Travere Therapeutics, Inc. Nov 28, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
| Mallinckrodt Hospital Products Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $6,060 |
| Akebia Therapeutics Inc Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,430 |
| Akebia Therapeutics Inc Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $858 |
| Akebia Therapeutics Inc Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $572 |
| Akebia Therapeutics Inc Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $572 |
| Novartis Pharmaceuticals Corporation Nov 21, 2025 | Consulting Fee Fabhalta; Vanrafia · Immunology | $2,600 |
| Mallinckrodt Hospital Products Inc. Nov 21, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to VERNON HILLS, IL · in-kind | $290 |
| Mallinckrodt Hospital Products Inc. Nov 20, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to VERNON HILLS, IL · in-kind | $587 |
| Mallinckrodt Hospital Products Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $6,060 |
| Travere Therapeutics, Inc. Nov 13, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
| Travere Therapeutics, Inc. Nov 13, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
| Mallinckrodt Hospital Products Inc. Nov 12, 2025 | Consulting Fee ACTHAR · IMMUNOLOGY | $6,060 |
| Akebia Therapeutics Inc Nov 12, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Tampa, FL · in-kind | $624 |
| Akebia Therapeutics Inc Nov 11, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Jacksonville, FL · in-kind | $782 |
| Travere Therapeutics, Inc. Nov 4, 2025 | Education Filspari · Kidney Disease · in-kind | $4.15 |
| Kyowa Kirin, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY | $2,975 |
| Mallinckrodt Hospital Products Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $3,030 |
| Akebia Therapeutics Inc Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,430 |
| Mallinckrodt Hospital Products Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $3,030 |
| Mallinckrodt Hospital Products Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $3,030 |
| Opko Pharmaceuticals, LLC Oct 24, 2025 | Education RAYALDEE · NEPHROLOGY · in-kind | $91.99 |
| Ardelyx, Inc. Oct 18, 2025 | Compensation for services other than consulting (speaking, faculty) XPHOZAH 30 MG · NEPHROLOGY | $3,040 |
| Ardelyx, Inc. Oct 18, 2025 | Travel and Lodging XPHOZAH 30 MG · NEPHROLOGY · travel to CHICAGO, IL · in-kind | $299 |
| Ardelyx, Inc. Oct 18, 2025 | Travel and Lodging XPHOZAH 30 MG · NEPHROLOGY · travel to CHICAGO, IL · in-kind | $284 |
| Opko Pharmaceuticals, LLC Oct 15, 2025 | Education RAYALDEE · NEPHROLOGY · in-kind | $54.35 |
| Mallinckrodt Hospital Products Inc. Oct 14, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to GREENSBORO, NC · in-kind | $609 |
| Mallinckrodt Hospital Products Inc. Oct 14, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to GREENSBORO, NC · in-kind | $395 |
| Mallinckrodt Hospital Products Inc. Oct 14, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to GREENSBORO, NC · in-kind | $340 |
| Mallinckrodt Hospital Products Inc. Oct 11, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to NASHVILLE, TN · in-kind | $64.24 |
| Akebia Therapeutics Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $4,004 |
| Akebia Therapeutics Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,144 |
| Mallinckrodt Hospital Products Inc. Oct 10, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to NASHVILLE, TN · in-kind | $874 |
| Mallinckrodt Hospital Products Inc. Oct 10, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to NASHVILLE, TN · in-kind | $352 |
| Mallinckrodt Hospital Products Inc. Oct 10, 2025 | Travel and Lodging ACTHAR · IMMUNOLOGY · travel to NASHVILLE, TN · in-kind | $263 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $579 |
| Novo Nordisk Inc Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,496 |
| Novo Nordisk Inc Oct 2, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Fort Lauderdale, FL · in-kind | $1,196 |
| Novartis Pharmaceuticals Corporation Sep 29, 2025 | Travel and Lodging Vanrafia · Nephrology · travel to Carolina, PR · in-kind | $496 |
| Novartis Pharmaceuticals Corporation Sep 29, 2025 | Travel and Lodging Vanrafia · Nephrology · travel to Carolina, PR | $25.20 |
| Novartis Pharmaceuticals Corporation Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) Vanrafia · Nephrology | $5,200 |
| Novartis Pharmaceuticals Corporation Sep 18, 2025 | Consulting Fee | $2,600 |
| Amgen Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $3,000 |
| Amgen Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $500 |
| Akebia Therapeutics Inc Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,430 |
| Akebia Therapeutics Inc Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $572 |
| Amgen Inc. Sep 12, 2025 | Travel and Lodging TAVNEOS · Inflammation · travel to Fernandina Beach, FL · in-kind | $935 |
| Akebia Therapeutics Inc Sep 8, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,430 |
| Akebia Therapeutics Inc Sep 5, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Orlando, FL | $48.00 |
| Akebia Therapeutics Inc Sep 5, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Orlando, FL | $25.20 |
| Akebia Therapeutics Inc Sep 4, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Nashville, TN · in-kind | $324 |
| Akebia Therapeutics Inc Sep 4, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Nashville, TN · in-kind | $211 |
| Akebia Therapeutics Inc Aug 28, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Tampa, FL · in-kind | $672 |
| Novartis Pharmaceuticals Corporation Aug 22, 2025 | Travel and Lodging Vanrafia · Nephrology · travel to Carolina, PR · in-kind | $745 |
| Novartis Pharmaceuticals Corporation Aug 22, 2025 | Travel and Lodging Vanrafia · Nephrology · travel to Carolina, PR · in-kind | $13.00 |
| Novo Nordisk Inc Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $3,679 |
| Novo Nordisk Inc Aug 7, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Satellite Beach, FL · in-kind | $1,297 |
| Novo Nordisk Inc Jul 27, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $3,543 |
| Novo Nordisk Inc Jul 27, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $280 |
| Novo Nordisk Inc Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,224 |
| Novo Nordisk Inc Jul 24, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Naples, FL · in-kind | $308 |
| Novo Nordisk Inc Jul 24, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Naples, FL · in-kind | $291 |
| Novo Nordisk Inc Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,224 |
| Novo Nordisk Inc Jul 23, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Fort Myers, FL · in-kind | $291 |
| Novartis Pharmaceuticals Corporation Jul 21, 2025 | Consulting Fee | $650 |
| Novartis Pharmaceuticals Corporation Jul 18, 2025 | Consulting Fee Fabhalta · Immunology | $7,200 |
| Novartis Pharmaceuticals Corporation Jul 18, 2025 | Travel and Lodging Fabhalta · Immunology · travel to JERSEY CITY, NJ | $325 |
| Novartis Pharmaceuticals Corporation Jul 18, 2025 | Travel and Lodging Fabhalta · Immunology · travel to JERSEY CITY, NJ · in-kind | $290 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Travel and Lodging travel to Jersey City, NJ · in-kind | $363 |
| Amgen Inc. Jul 2, 2025 | Travel and Lodging TAVNEOS · Inflammation · travel to HIALEAH, FL | $347 |
| Akebia Therapeutics Inc Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,430 |
| Akebia Therapeutics Inc Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,144 |
| AstraZeneca Pharmaceuticals LP Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) LOKELMA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $1,600 |
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee Fabhalta · Immunology | $3,738 |
| Akebia Therapeutics Inc Jun 25, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Fort Myers, FL · in-kind | $1,166 |
| Kyowa Kirin, Inc. Jun 18, 2025 | Travel and Lodging CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY · travel to CHICAGO, IL | $59.20 |
| Kyowa Kirin, Inc. Jun 18, 2025 | Travel and Lodging CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY · travel to CHICAGO, IL | $49.40 |
| Kyowa Kirin, Inc. Jun 18, 2025 | Travel and Lodging CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY · travel to CHICAGO, IL | $22.50 |
| Kyowa Kirin, Inc. Jun 18, 2025 | Travel and Lodging CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY · travel to CHICAGO, IL | $22.08 |
| AstraZeneca Pharmaceuticals LP Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) LOKELMA · Cardiovascular and Metabolism Company’s descriptionSpeaker Fee | $2,800 |
| Amgen Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $3,000 |
| AstraZeneca Pharmaceuticals LP Jun 12, 2025 | Travel and Lodging LOKELMA · Cardiovascular and Metabolism · travel to Saint Petersburg, FL · in-kind Company’s descriptionSpeaker Expenses | $805 |
| Amgen Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $500 |
| Mallinckrodt Hospital Products Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) ACTHAR · IMMUNOLOGY | $2,020 |
| Opko Pharmaceuticals, LLC Jun 6, 2025 | Education RAYALDEE · NEPHROLOGY · in-kind | $5.45 |
| Ani Pharmaceuticals, Inc. May 29, 2025 | Honoraria ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated | $1,800 |
| Amgen Inc. May 29, 2025 | Travel and Lodging TAVNEOS · Inflammation · travel to HIALEAH, FL · in-kind | $455 |
| Akebia Therapeutics Inc May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,430 |
| Travere Therapeutics, Inc. May 22, 2025 | Education Filspari · Kidney Disease · in-kind | $16.89 |
| Opko Pharmaceuticals, LLC May 15, 2025 | Education RAYALDEE · NEPHROLOGY · in-kind | $5.45 |
| Kyowa Kirin, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY | $4,016 |
| Kyowa Kirin, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY | $3,570 |
| Novo Nordisk Inc Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $5,586 |
| Novo Nordisk Inc Apr 30, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Sarasota, FL · in-kind | $1,025 |
| Kyowa Kirin, Inc. Apr 26, 2025 | Travel and Lodging CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY · travel to CHICAGO, IL · in-kind | $305 |
| Kyowa Kirin, Inc. Apr 26, 2025 | Travel and Lodging CRYSVITA · FIBROBLAST GROWTH FACTOR 23 FGF23 BLOCKING ANTIBODY · travel to CHICAGO, IL · in-kind | $187 |
| Novo Nordisk Inc Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,496 |
| Novo Nordisk Inc Apr 9, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Boca Raton, FL · in-kind | $1,149 |
| Novo Nordisk Inc Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $3,543 |
| Kyowa Kirin, Inc. Mar 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,355 |
| Kyowa Kirin, Inc. Mar 20, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $349 |
| Kyowa Kirin, Inc. Mar 20, 2025 | Travel and Lodging travel to MIAMI, FL | $328 |
| Kyowa Kirin, Inc. Mar 20, 2025 | Travel and Lodging travel to MIAMI, FL | $57.18 |
| Kyowa Kirin, Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $893 |
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $4,987 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $399 |
| Akebia Therapeutics Inc Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,430 |
| Akebia Therapeutics Inc Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,144 |
| Akebia Therapeutics Inc Mar 5, 2025 | Travel and Lodging Vafseo · Nephrology · travel to Naples, FL · in-kind | $1,201 |
| Novartis Pharmaceuticals Corporation Feb 28, 2025 | Consulting Fee | $11,350 |
| Novartis Pharmaceuticals Corporation Feb 28, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $251 |
| Novartis Pharmaceuticals Corporation Feb 28, 2025 | Travel and Lodging travel to JERSEY CITY, NJ | $157 |
| Novartis Pharmaceuticals Corporation Feb 28, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $48.00 |
| Novartis Pharmaceuticals Corporation Feb 27, 2025 | Travel and Lodging Fabhalta · Immunology · travel to Jersey City, NJ · in-kind | $421 |
| Akebia Therapeutics Inc Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $2,288 |
| Akebia Therapeutics Inc Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) Vafseo · Nephrology | $1,144 |
| Amgen Inc. Jan 16, 2025 | Compensation for services other than consulting (speaking, faculty) TAVNEOS · Inflammation | $3,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 13 companies. The companies reported $2,112,210 in research payments for these studies, mostly to the institutions running them.
- An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases…
Vertex Pharmaceuticals Incorporated - A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)
Vertex Pharmaceuticals Incorporated - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Amgen Inc. - A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidne…
Vertex Pharmaceuticals Incorporated - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.